IMblaze 370: lessons learned and future strategies in colorectal cancer treatment

Mark McGregor¹, Timothy J Price^{1

2}

Affiliations

¹ Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.
² University of Adelaide, School of Medicine, Adelaide, Australia.

Editorial

Mark McGregor et al. Ann Transl Med. 2019 Nov.

. 2019 Nov;7(21):602.

doi: 10.21037/atm.2019.08.119.

Mark McGregor¹, Timothy J Price^{1

2}

¹ Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.
² University of Adelaide, School of Medicine, Adelaide, Australia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Eng C, et al. Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Lancet Oncol. 2019. PMID: 31003911 Clinical Trial.

1. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372:1909-19. 10.1056/NEJMoa1414325 - DOI - PubMed
1. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12. 10.1016/S0140-6736(12)61900-X - DOI - PubMed
1. Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2019;20:849-61. 10.1016/S1470-2045(19)30027-0 - DOI - PubMed
1. Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol 2016;34:abstr 3502.
1. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20. 10.1056/NEJMoa1500596 - DOI - PMC - PubMed